Cho, Nicholas S.
Hagiwara, Akifumi
Sanvito, Francesco
Ellingson, Benjamin M. http://orcid.org/0000-0002-2764-6640
Funding for this research was provided by:
NIH/NCI (R21CA223757, P50CA211015, R01CA270027)
NIH-NIGMS (T32 GM008042)
American Brain Tumor Association (MSSF2100033)
Article History
Received: 15 August 2022
Accepted: 14 October 2022
First Online: 27 October 2022
Compliance with ethical standards
:
: BME, paid advisor and consultant for Medicenna, MedQIA, Neosoma, Servier Pharmaceuticals, Siemens, Janssen, Imaging Endpoints, Kazia, VBL, Oncoceutics/Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Global Coalition for Adaptive Research (GCAR), Alpheus Medical, Inc., Curtana Pharma, and Sagimet Biosciences. Grant funding is from Siemens, Servier/Agios, Neosoma, and Janssen. The other authors declare no competing interests.
: The study was performed in compliance with the Health Insurance Portability and Accountability Act and with the ethical standards of the 1964 Helsinki Declaration and its later amendments or comparable standards.
: Informed consent was obtained from all participants to be part of our institutional review board approved clinical database (IRB no. 11-001427).